Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Targeted cancer therapies are limited by the unique metabolic requirements of cancer cells.
• Developing specific inhibitors that exploit these metabolic differences is crucial for effective cancer treatment.

Purpose of the Study:

• To identify and characterize a novel small molecule inhibitor, Gboxin, with specificity for glioblastoma cells.
• To elucidate the mechanism of action of Gboxin in cancer cells and evaluate its therapeutic potential.

Main Methods:

• Gboxin was tested against primary mouse and human glioblastoma cells, as well as control cell lines (mouse embryonic fibroblasts, neonatal astrocytes).
• Oxygen consumption assays were performed to assess Gboxin's impact on cellular respiration.
• Studies investigated Gboxin's interaction with mitochondrial components, including oxidative phosphorylation complexes and ATP synthase.
• Gboxin-resistant cells were analyzed to understand resistance mechanisms involving the mitochondrial permeability transition pore.
• In vivo studies utilized Gboxin analogues in glioblastoma allograft and patient-derived xenograft models.

Main Results:

• Gboxin selectively inhibited the growth of glioblastoma cells, sparing normal cells.
• Gboxin rapidly and irreversibly inhibited oxygen consumption in glioblastoma cells.
• The molecule targets the F0F1 ATP synthase by associating with mitochondrial oxidative phosphorylation complexes, dependent on the inner mitochondrial membrane proton gradient.
• Gboxin resistance was linked to a functional mitochondrial permeability transition pore, which regulates pH and prevents Gboxin accumulation.
• A stable Gboxin analogue demonstrated efficacy in inhibiting glioblastoma in vivo models.
• Gboxin exhibited toxicity against diverse human cancer cell lines, indicating broader applicability.

Conclusions:

• Gboxin represents a promising cancer-specific inhibitor targeting the unique metabolic vulnerabilities of glioblastoma.
• The mechanism involves disruption of mitochondrial ATP synthesis via F0F1 ATP synthase inhibition.
• Exploiting the elevated proton gradient and pH in cancer cell mitochondria presents a viable strategy for developing novel antitumour agents.